Parabilis Medicines, Inc. (PBLS)
NasdaqGS
Price as at 30 Sept 2026, 22:57 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Parabilis Medicines, Inc. trades at $32.29. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its PBLS data?
Fundamentals for PBLS come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 22:57 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for PBLS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.